Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05169112
PHASE3

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Sponsor: Ottawa Hospital Research Institute

View on ClinicalTrials.gov

Summary

Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.

Official title: The Impact of Adjuvant Androgen Deprivation Following Radical Prostatectomy on Prostate Cancer Recurrence

Key Details

Gender

MALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

72

Start Date

2023-03-06

Completion Date

2028-11

Last Updated

2025-03-20

Healthy Volunteers

No

Conditions

Interventions

DRUG

Lupron Depot

Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months

Locations (3)

Nova Scotia Health

Halifax, Nova Scotia, Canada

The Ottawa Hospital

Ottawa, Ontario, Canada

Centre universitaire de santé McGill - McGill University Health Centre

Montreal, Quebec, Canada